Lyell Immunopharma Will Acquire ImmPACT Bio and Prioritizes Its Pipeline to Focus on Next-Generation CAR T-cell Therapies 

Lyell Immunopharma, a cell therapy developer that has struggled to match its high profile, is acquiring a biotechnology startup and streamlining research in a bid to focus on a slate of cellular immunotherapies for cancer. The company said it’s reached a deal to buy ImmPact Bio, a cell therapy startup that’s been focused on cancer and autoimmune diseases, for $30M in cash and 37.5M shares of Lyell stock.